沃森生物：与玉溪国有资本运营公司签署战略合作框架协议 7月23日晚，沃森生物（300142）发布公告称，公司与玉溪国有资本运营有限公司签署了《战略合作框 架协议》。双方拟围绕疫苗及生物制品产业领域建立长期合作关系，通过共同设立股权投资基金、参与 产业链企业投资、战略入股等多种方式深化合作。此次合作旨在推动公司在创新疫苗及合成生物制造行 业的产业升级和业务扩张。 资料显示，沃森生物成立于2001年1月，主营业务是人用疫苗等生物技术药的研发、生产和销售。 所属行业：医药生物–生物制品–疫苗 苑东生物：初步确定询价转让价格为42.06元/股 7月23日晚，苑东生物（688513）发布公告称，公司股东询价转让初步定价为42.06元/股。本次询价转 让共吸引12家机构投资者参与，涵盖基金、保险、证券及私募基金等专业机构，合计有效认购股份数量 为540万股，有效认购倍数为1.60倍。拟受让方为10家机构投资者，拟受让股份总数为336.955万股。 资料显示，苑东生物成立于2009年6月，主营业务是化学原料药、高端化学药品及生物药品研发、生 产、销售。 所属行业：医药生物–化学制药–化学制剂 伟明环保：上半年完成发电量22 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-036 北京康辰药业股份有限公司 关于全资子公司对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 标的公司：Nuance Biotech（以下简称"优锐开曼"） ? 投资金额：15,000 万元人民币（租金出资 5,000 万，现金出资 10,000 万 元） 辰药业"）全资子公司康辰药业（香港）有限公司（以下简称："康辰香港"） 与 交 易 标 的 优 锐 开 曼 及 其 下 属 子 公 司 共 同 签 署 了 《 Series E Preferred Share Purchase Agreement》（以下简称"《股份认购协议》"），康辰香港拟以 15,000 万元人民币价格，参与优锐开曼 E 轮融资，认购优锐开曼新发行的 38,439,537 股 E 轮优先股。本轮融资募集资金将用于优锐开曼业务拓展、资本支出与营运 资金等，以支持其创新药申报上市，以及满足其他经营资金需求。 本次交易出资情况为：优锐开曼下属子公司优锐生物 ...

北京康辰药业股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 北京康辰药业股份有限公司（以下简称"公司"）股票于 2025 年 7 月 18 日、7 月 21 日、7 月 22 日连续 3 个交易日收盘价格涨幅偏离值累计超过 20%， 属于股票交易异常波动情形。 经公司自查，并书面征询控股股东、实际控制人，截至本公告披露日， 除本公司已披露事项外，不存在应披露而未披露的重大信息。 其他核查事项具体详见本公告中"二、公司关注并核实的相关情况"之"（四） 其他核查事项"。 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-035 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、 股票交易异常波动的具体情况 公司股票交易于 2025 年 7 月 18 日、7 月 21 日、7 月 22 日连续 3 个交易日 收盘价格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规 定，属于股票交易异常波动情形。 二、 公司关注并核实的相关情况 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-036 北京康辰药业股份有限公司 关于全资子公司对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 标的公司：Nuance Biotech（以下简称"优锐开曼"） 投资金额：15,000 万元人民币（租金出资 5,000 万，现金出资 10,000 万 元） 特别风险提示：目前，Nuance Biotech（优锐开曼）近 5 年未盈利，且其 引入开发的创新药恩司芬群（Ensifentrine）目前尚处在准备申报境内上市阶段。 Nuance Biotech（优锐开曼）未来是否实现盈利，以及恩司芬群（Ensifentrine） 是否能够获批上市，尚存在不确定性；受其他行业发展、技术水平、监管政策等 多种因素影响，Nuance Biotech（优锐开曼）后续发展可能存在无法达到投资预 期的风险。敬请广大投资者理性投资，注意投资风险。 一、 对外投资概述 2025 年 7 月 21 日，北京康辰药业股份有限公司（以下简称："公司"或"康 辰 ...

A股创新药概念午后表现回暖，益方生物、诺诚健华涨超6%，一品红、新诺威、百济神州、博瑞医 药、康辰药业均涨逾5%。 ...

Core Viewpoint - The announcement from Beijing Kangchen Pharmaceutical Co., Ltd. highlights the recent abnormal fluctuations in its stock price and reassures investors about the company's stable operational status while urging caution in trading activities [1][2]. Group 1: Production and Operational Status - The company confirms that its production and operational activities are normal, with no significant changes or undisclosed major events apart from previously disclosed information [1]. Group 2: Stock Market Trading Risks - The company's stock experienced a cumulative price increase deviation of over 20% across three consecutive trading days (July 9, 10, and 11, 2025), indicating abnormal trading activity [1]. - On July 14, 2025, the company's stock hit the daily limit up again, reflecting significant short-term price increases, prompting a warning for investors to be mindful of trading risks [1]. Group 3: Other Risks and Developments - The company has secured exclusive rights for clinical development and commercialization of Ensifentrine (Ohtuvayre™) in Greater China, a novel drug for treating chronic obstructive pulmonary disease (COPD) [2]. - Merck announced the acquisition of Verona Pharma for approximately $10 billion on July 9, 2025, which may impact the market landscape [2]. - The company's subsidiary holds a 4.96% stake in Nuance Biotech, which has not been profitable in the past five years, indicating that this investment is unlikely to significantly affect the company's overall performance [2].

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-034 北京康辰药业股份有限公司 关于股票交易风险提示的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经公司自查，公司目前生产经营活动一切正常，日常经营情况未发生重大变 化，除已披露信息外，不存在其他应披露而未披露的重大事项。 二、二级市场交易风险 公司股票于 2025 年 7 月 9 日、7 月 10 日、7 月 11 日连续三个交易日收盘价 格涨幅偏离值累计超过 20%，属于股票交易异常波动情形。2025 年 7 月 14 日， 公司股票再次涨停，短期内涨幅较大，敬请广大投资者注意二级市场交易风险， 理性投资。 三、其他风险 北京康辰药业股份有限公司（以下简称"公司"）股票于 2025 年 7 月 9 日、 7 月 10 日、7 月 11 日连续 3 个交易日收盘价格涨幅偏离值累计超过 20%，属于 股票交易异常波动情形。公司已于 2025 年 7 月 12 日披露了《股票交易异常波动 公告》（公告编号：2025-033)。 2025 年 7 月 ...

New Stock Issuance - Shanda Electric (Stock Code: 301609) issued at a price of 14.66[1] - Jiyuan Group (Stock Code: 732262) issued at a price of 10.88[1] Market Alerts - Jichuan Pharmaceutical (Stock Code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - The last trading day for Tuisan Jinguang (Stock Code: 600190) is July 14, 2025, with 4 trading days remaining[1] - The last trading day for Tuisan Jinjing (Stock Code: 900952) is also July 14, 2025, with 4 trading days remaining[1] Abnormal Fluctuations - *ST Zitian (Stock Code: 300280) reported severe abnormal fluctuations on July 10, 2025[1] - *ST Yushun (Stock Code: 002289) reported abnormal fluctuations on July 11, 2025[1] Other Notable Announcements - Longyuan Green Energy (Stock Code: 603185) announced on July 11, 2025[1] - Kedi Pharmaceutical (Stock Code: 000590) announced on July 14, 2025[1]

Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]

Core Viewpoint - Beijing Kangchen Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days from July 9 to July 11, 2025, indicating abnormal trading activity [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly, with a cumulative closing price deviation exceeding 20% over three consecutive trading days [1]. - The company conducted a self-examination and confirmed that there were no undisclosed significant information related to the stock price fluctuations [2]. Group 2: Business Operations - The company's production and operational activities are reported to be normal, with no significant changes in daily operations [1]. - There are no major undisclosed events such as asset restructuring, stock issuance, or significant business collaborations that could impact the stock price [2]. Group 3: Sensitive Information - During the period of stock price fluctuation, company executives and major shareholders did not engage in buying or selling the company's stock [2]. - The company holds a 4.96% stake in Nuance Biotech and has exclusive rights for the clinical development and commercialization of Ensifentrine in Greater China, valued at approximately $10 billion [2].